JP7696617B2 - 細胞競合の制御剤 - Google Patents

細胞競合の制御剤 Download PDF

Info

Publication number
JP7696617B2
JP7696617B2 JP2021509704A JP2021509704A JP7696617B2 JP 7696617 B2 JP7696617 B2 JP 7696617B2 JP 2021509704 A JP2021509704 A JP 2021509704A JP 2021509704 A JP2021509704 A JP 2021509704A JP 7696617 B2 JP7696617 B2 JP 7696617B2
Authority
JP
Japan
Prior art keywords
cells
lilrb3
protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021509704A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020196926A1 (https=
Inventor
剛 丸山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPWO2020196926A1 publication Critical patent/JPWO2020196926A1/ja
Application granted granted Critical
Publication of JP7696617B2 publication Critical patent/JP7696617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021509704A 2019-03-28 2020-03-30 細胞競合の制御剤 Active JP7696617B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019063594 2019-03-28
JP2019063594 2019-03-28
JP2019069777 2019-04-01
JP2019069777 2019-04-01
PCT/JP2020/014715 WO2020196926A1 (ja) 2019-03-28 2020-03-30 細胞競合の制御剤

Publications (2)

Publication Number Publication Date
JPWO2020196926A1 JPWO2020196926A1 (https=) 2020-10-01
JP7696617B2 true JP7696617B2 (ja) 2025-06-23

Family

ID=72609511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509704A Active JP7696617B2 (ja) 2019-03-28 2020-03-30 細胞競合の制御剤

Country Status (5)

Country Link
US (1) US20220233638A1 (https=)
EP (1) EP3949993A4 (https=)
JP (1) JP7696617B2 (https=)
CN (1) CN113939316A (https=)
WO (1) WO2020196926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219474A1 (ja) * 2023-04-21 2024-10-24 株式会社Logomix Ｋｉｒ遺伝子クラスター領域、ｌｉｌｒ遺伝子クラスター領域およびｋｌｒ遺伝子クラスター領域のいずれか１以上の領域において欠失を有する細胞およびその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517330A (ja) 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片
JP2018510340A (ja) 2015-03-06 2018-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2018119425A2 (en) 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
US20070281327A1 (en) 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
EP2854723B1 (en) 2012-05-25 2017-07-19 Coloplast A/S Comfort layer for a collecting bag
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
JP6188244B2 (ja) 2012-12-27 2017-08-30 テイ・エス テック株式会社 シート装置
CA2959821C (en) * 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
US11906519B2 (en) * 2016-07-29 2024-02-20 The Board Of Regents Of The University Of Texas System Methods for identifying LILRB-blocking antibodies
CN111867614A (zh) * 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517330A (ja) 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片
JP2018510340A (ja) 2015-03-06 2018-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2018119425A2 (en) 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Asian-Australas J Anim Sci，2019年05月，Vol. 32, No. 5，pp. 614-628，<URL: https://doi.org/10.5713/ajas.18.0561>
BLOOD，2009年，Vol. 114, No. 11，pp. 2323-2332
J Immunol，1998年，Vol. 160, No. 7，pp. 3096-3100，<URL: https://doi.org/10.4049/jimmunol.160.7.3096>
SCIENCE，1991年，Vol. 252，pp. 1424-1427
Tissue Antigens，2004年，Vol. 64，pp. 215-225，doi: 10.1111/j.1399-0039.2004.00290.x

Also Published As

Publication number Publication date
EP3949993A4 (en) 2023-07-05
US20220233638A1 (en) 2022-07-28
EP3949993A1 (en) 2022-02-09
CN113939316A (zh) 2022-01-14
JPWO2020196926A1 (https=) 2020-10-01
WO2020196926A1 (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7186196B2 (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
US9241991B2 (en) Agents, compositions, and methods for treating pruritus and related skin conditions
BR112020026386A2 (pt) Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
KR102940898B1 (ko) 대식세포 분화 및 면역의 변형 방법
US11078277B2 (en) Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
TW202330019A (zh) 用於治療自體免疫疾病及癌症之組成物及方法
JP7330174B2 (ja) オートファジーをモジュレーションするための方法及び医薬組成物
EP3124035B1 (en) Novel cancer antigen eef2
US20190055560A1 (en) Fats as a target for treating tumors and uses thereof
US20130028896A1 (en) Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses
EP2876160B1 (en) Differentiation marker for and differentiation control for ocular cells
JP7696617B2 (ja) 細胞競合の制御剤
US20210000921A1 (en) Methods and compositions for modulating thymic function
Rawat et al. The CD200-CD200R cross-talk helps Leishmania donovani to down regulate macrophage and CD4+ CD44+ T cells effector functions in an NFκB independent manner
JPWO2014126127A1 (ja) ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法
KR20220095112A (ko) Mdsc 활성 저해 약물의 선별 방법
US20250297310A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
US20230034732A1 (en) Targeting cell tropism receptors to inhibit cytomegalovirus infection
KR102352127B1 (ko) Mitf 억제제를 유효성분으로 함유하는 골수-유래 억제세포 저해용 조성물
Wang et al. CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy
JP2016088926A (ja) Ｉｋａｒｏｓ阻害に基づく抗炎症薬
JP7825631B2 (ja) 細胞外小胞の分泌を促進する細胞外小胞分泌促進剤、およびその用途
WO2025134119A1 (en) Reprogrammed dysfunctional natural killer cells and uses thereof
CN115867315A (zh) 用于抑制细胞外囊泡的分泌的细胞外囊泡分泌抑制剂及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250604

R150 Certificate of patent or registration of utility model

Ref document number: 7696617

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150